ATE307209T1 - Polypeptide die fähig sind an cd64 zu binden und die ein oder mehrere heterologe t zellepitope enthalten, und deren verwendungen - Google Patents

Polypeptide die fähig sind an cd64 zu binden und die ein oder mehrere heterologe t zellepitope enthalten, und deren verwendungen

Info

Publication number
ATE307209T1
ATE307209T1 AT02715584T AT02715584T ATE307209T1 AT E307209 T1 ATE307209 T1 AT E307209T1 AT 02715584 T AT02715584 T AT 02715584T AT 02715584 T AT02715584 T AT 02715584T AT E307209 T1 ATE307209 T1 AT E307209T1
Authority
AT
Austria
Prior art keywords
heterologue
polypeptides
capability
binding
cell epitopes
Prior art date
Application number
AT02715584T
Other languages
English (en)
Inventor
Linda Gillian Durrant
Tina Parsons
Adrian Robins
Original Assignee
Scancell Ltd
Cancer Res Campaign Tech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scancell Ltd, Cancer Res Campaign Tech filed Critical Scancell Ltd
Application granted granted Critical
Publication of ATE307209T1 publication Critical patent/ATE307209T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • C07K16/4266—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig against anti-tumor receptor Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Jellies, Jams, And Syrups (AREA)
AT02715584T 2001-01-26 2002-01-28 Polypeptide die fähig sind an cd64 zu binden und die ein oder mehrere heterologe t zellepitope enthalten, und deren verwendungen ATE307209T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0102145.0A GB0102145D0 (en) 2001-01-26 2001-01-26 Substances
PCT/GB2002/000354 WO2002058728A2 (en) 2001-01-26 2002-01-28 Polypeptides capable of binding to cd64 and comprising one or more heterologous t cell epitopes, and their uses

Publications (1)

Publication Number Publication Date
ATE307209T1 true ATE307209T1 (de) 2005-11-15

Family

ID=9907631

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02715584T ATE307209T1 (de) 2001-01-26 2002-01-28 Polypeptide die fähig sind an cd64 zu binden und die ein oder mehrere heterologe t zellepitope enthalten, und deren verwendungen

Country Status (12)

Country Link
US (2) US20040146505A1 (de)
EP (1) EP1354054B1 (de)
JP (1) JP5198715B2 (de)
KR (1) KR20030083698A (de)
AT (1) ATE307209T1 (de)
AU (1) AU2002225230B2 (de)
CA (1) CA2435672C (de)
DE (1) DE60206731T2 (de)
DK (1) DK1354054T3 (de)
ES (1) ES2254663T3 (de)
GB (1) GB0102145D0 (de)
WO (1) WO2002058728A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL371202A1 (en) * 2002-04-09 2005-06-13 Merck Patent Gmbh Anti-idiotype anti-cea antibody molecules and its use as cancer vaccine
AT502293B1 (de) * 2002-05-15 2008-03-15 Igeneon Krebs Immuntherapie Immunogener, monoklonaler antikörper
DE602004030617D1 (de) * 2003-11-26 2011-01-27 Fraunhofer Ges Forschung Rekombinante anti-cd64-eta' immunotoxine
JP4855163B2 (ja) 2006-01-18 2012-01-18 新日本製鐵株式会社 ほうろう加工品
GB0605735D0 (en) * 2006-03-22 2006-05-03 Immunobiology Ltd Composition and method for mediating an immune response
GB0706070D0 (en) * 2007-03-28 2007-05-09 Scancell Ltd Nucleic acids
GB201214007D0 (en) 2012-08-07 2012-09-19 Scancell Ltd Anti-tumour immune responses to modified self-epitopes
AU2016215604B2 (en) 2015-02-02 2020-08-13 The University Of Birmingham Targeting moiety peptide epitope complexes having a plurality of T-cell epitopes
GB201815041D0 (en) 2018-09-14 2018-10-31 Scancell Ltd Epitopes
CA3118692A1 (en) 2018-11-06 2020-05-14 Alsatech, Inc. Cell-based gene therapy for neurodegenerative diseases
GB202005779D0 (en) 2020-04-21 2020-06-03 Scancell Ltd Anti-tumour immune responses
WO2022043400A1 (en) 2020-08-26 2022-03-03 Scancell Limited Nucleic acids encoding a polypeptide comprising a modified fc region of a human igg1 and at least one heterologous antigen
GB202018395D0 (en) 2020-11-23 2021-01-06 Scancell Ltd Immunotherapy

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69023900D1 (de) * 1989-02-24 1996-01-11 Univ California Gentechnologisch veränderte immunglobuline.
US5969109A (en) * 1990-02-28 1999-10-19 Bona; Constantin Chimeric antibodies comprising antigen binding sites and B and T cell epitopes
WO1992018540A1 (en) * 1991-04-18 1992-10-29 Mount Sinai School Of Medicine Of The City University Of New York Anti-human immunodeficiency virus recombinant antibodies
DK0759944T3 (da) 1994-05-13 2001-11-26 Biovation Ltd Forbedringer af og relateret til peptidfremføring
US20080318254A9 (en) * 1997-03-10 2008-12-25 The Regents Of The University Of California PSCA antibodies and hybridomas producing them
WO2000064488A2 (en) * 1999-04-27 2000-11-02 Eurogen Holding, S.A. Somatic transgene immunization and related methods
US7067110B1 (en) * 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US20040248113A1 (en) * 1999-12-28 2004-12-09 Alessandro Sette Method and system for optimizing multi-epitope nucleic acid constructs and peptides encoded thereby

Also Published As

Publication number Publication date
EP1354054A2 (de) 2003-10-22
JP2004520376A (ja) 2004-07-08
DE60206731T2 (de) 2006-07-20
US8187600B2 (en) 2012-05-29
EP1354054B1 (de) 2005-10-19
ES2254663T3 (es) 2006-06-16
CA2435672A1 (en) 2002-08-01
GB0102145D0 (en) 2001-03-14
AU2002225230B2 (en) 2007-08-16
US20040146505A1 (en) 2004-07-29
WO2002058728A2 (en) 2002-08-01
US20110165180A1 (en) 2011-07-07
CA2435672C (en) 2013-10-29
KR20030083698A (ko) 2003-10-30
JP5198715B2 (ja) 2013-05-15
DK1354054T3 (da) 2006-02-13
DE60206731D1 (de) 2006-03-02
WO2002058728A3 (en) 2002-10-03

Similar Documents

Publication Publication Date Title
DE60206731D1 (de) Polypeptide die fähig sind an cd64 zu binden und die ein oder mehrere heterologe t zellepitope enthalten, und deren verwendungen
DK1572748T3 (da) Humaniseret antistof (H14.18) af muse-14.18-antistof der binder til GD2 og dets fusionsprotein med IL-2
DK0784683T3 (da) TIE-2-ligander, fremgangsmåder til dannelse af disse og anvendelser deraf
EP1383785A4 (de) Rekombinanter, tumorspezifischer antikörper und dessen verwendung
DK0643726T3 (da) Peptider af humant p53-protein til anvendelse i sammensætninger, som inducerer humant T-celle-respons, og humane p53-protei
DK43890D0 (da) Nucleinsyre, vektorer og celler indeholdende den, derudfra fremstillede produkter og disses anvendelse
DE60032486D1 (de) Prion protein peptide und deren verwendung
BR0008161A (pt) Uso de uma composição terapêutica para tratamento de uma célula tumoral, composição terapêutica, e kit para tratamento de uma célula tumoral
HUP9802212A2 (hu) Humán terápiában alkalmazható rekombináns anti-CD4-ellenanyagok
DE60018761D1 (de) Therapeutische antikörper gegen das muc-1 antigen und verfahren zu deren verwendung
ATE431746T1 (de) Verwendung cd28 spezifischer monoklonaler antikörper zur stimulation von blutzellen, welche kein cd28 tragen
ATE132197T1 (de) Monoklonale antikörper
ATE378356T1 (de) Gangliosid-assoziierte rekombinante antikörper und deren verwendung bei der diagnose und behandlung von tumoren
IL163902A0 (en) Antibodies against cancer antigen tmeff2 and uses thereof
ATE490785T1 (de) Parathormon-antikörper und damit zusammenhängende verfahren
WO2021226289A3 (en) Compositions and methods for tcr reprogramming using cd70 specific fusion proteins
IL177069A (en) ANTI-EpCAM IMMUNOGLOBULINS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
DE60204755D1 (de) "3,7-diazabicyclo(3.3.0)octane und deren verwendung bei der behandlung von herzrhythmusstörungen"
TW272197B (de)
WO2003054019A3 (en) Therapeutic monoclonal anti-tirc7 antibodies for use in immune related and other diseases
DE60227367D1 (de) Modifizierter granulozyten stimulierender factor (g-csf) mit verringerter immunogenität
DE50210279D1 (de) Screeningverfahren mit bnpi und dnpi
WO2025222087A3 (en) Klrb1 binding agents and methods of use thereof
DE59805440D1 (de) Verwendung von lbp zur sepsistherapie

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1354054

Country of ref document: EP